Author/Editor     Fuerst, Jurij; Peklar, Jure
Title     Farmakoepidemiološki vidik zdravljenja hiperlipidemij
Translated title     Pharmacoepidemiology of treatment of hyperlipidemy
Type     članek
Source     Farm Vestn
Vol. and No.     Letnik 54, št. Poseb št
Publication year     2003
Volume     str. 145-50
Language     slo
Abstract     HMGCo-A reductase inhibitors - statins are among most ambulatory prescribed drugs with total cost 6,3 billion 5IT in year 2002. In public funds they can be prescribed only according to special limitations. One or more boxes of statins has been prescribed to 162.301 individuals, but most frequent were prescribed in age range from 60 to 69 years. First among health regions is Ljubljana but the last in prescribing is Nova Gorica. For primary preventive cardio-vascular diseases statins should be prescribed to 48.000 individuals and approximately 80.000 diabetics. In aim of secondary preventive statins should be prescribed to 307.851 individuals, so together approximately 435.851. Now statins are prescribed only to 37% of the population at high risk. Therefore we can expect substantial growth of amount of drug prescribed in next future and strategy of controlling of increasing drug expenses is necessary to be made.
Summary     Zaviralci HMGCo-A ali popularno imenovani statini so med najpogosteje ambulantno predpisanimi zdravili, njihova celotna vrednost v 1. 2002 je bila 6,3 milijarde SIT. V breme obveznega zdravstvenega zavarovanja jih je mogoče predpisovati le v okviru omejitve predpisovanja. V 1. 2001 je prejelo vsaj en omot statina 162.301 oseb. Najpogosteje so predpisani v starostni skupini 60-69 let. Največja poraba na prebivalca je v območni enoti (OE) Ljubljana, najnižja v OE Nova Gorica. V okviru primarne preventive srčno-žilnih bolezni bi potrebovalo statin 48.000 oseb, prav tako pa tudi okrog 80.000 diabetikov. V okviru sekundarne preventive bi potrebovalo statin 307.851 oseb, torej skupno 435.851 oseb. Prejema jih okoli 37% vseh, ki bi jim statini lahko koristili. Zato lahko pričakujemo še bistveno zvišanje predpisovanja statinov. Nujno je pripraviti strategijo, ki bo omogočila boljše obvladovanje pričakovanih naraščajočih izdatkov za zdravila.
Descriptors     HYPERLIPIDEMIA
ANTILIPEMIC AGENTS
PHARMACOEPIDEMIOLOGY
CARDIOVASCULAR DISEASES